Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 597 participants.
Also called NCT05886088
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 597 participants
- Sponsor
- EMS
- Registry
-
NCT05886088
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05886088. Randomized; quadruple masking; primary purpose treatment. Start 2024-02 (anticipated); primary completion 2026-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
- Acronym
- DÁLIA
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LID104
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Linagliptin
- Lead sponsor
- EMS
Record details
- Record id
cardio:ct-nct05886088- Content hash
72d6b25813519cf6bf52bee72a0650d3c768ad56207aca4f8a690197a42c2a22